New prescription medication gaps: a comprehensive measure of adherence to new prescriptions
- PMID: 19500161
- PMCID: PMC2754552
- DOI: 10.1111/j.1475-6773.2009.00989.x
New prescription medication gaps: a comprehensive measure of adherence to new prescriptions
Abstract
Objective: Describe a novel approach to comprehensively summarize medication adherence.
Data sources/study setting: Kaiser Permanente Northern California Diabetes Registry (n approximately 220,000)
Study design: In a new prescription cohort design (27,329 subjects prescribed new medications), we used pharmacy utilization data to estimate adherence during 24 months follow-up. Proportion of time without sufficient medications (medication gaps) was estimated using a novel measure (New Prescription Medication Gaps [NPMG]) and compared with a traditional measure of adherence.
Data collection/extraction methods: Data derived from electronic medical records and survey responses.
Principal findings: Twenty-two percent of patients did not become ongoing users (had zero or only one dispensing of the new prescription). The proportion of newly prescribed patients that never became ongoing users was eightfold greater than the proportion who maintained ongoing use, but with inadequate adherence. Four percent of those with at least two dispensings discontinued therapy during the 24 months follow-up. NPMG was significantly associated with high out-of-pocket costs, self-reported adherence, and clinical response to therapy.
Conclusions: NPMG is a valid adherence measure. Findings also suggest a larger burden of inadequate adherence than previously thought. Public health efforts have traditionally focused on improving adherence in ongoing users; clearly more attention is needed to address nonpersistence in the very first stages after a new medication is prescribed.
Figures


Comment in
-
Research and reform: toward a high-value health system.Health Serv Res. 2009 Oct;44(5 Pt 1):1445-8. doi: 10.1111/j.1475-6773.2009.01016.x. Health Serv Res. 2009. PMID: 19735528 Free PMC article. No abstract available.
References
-
- Avorn J, Bohn RL, Lacour A, Monane M, Mogun H, LeLorier J. Persistence of Use of Lipid-Lowering Medications. Journal of the American Medical Association. 1998;279(18):1458–62. - PubMed
-
- Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-Term Persistence in Use of Statin Therapy in Elderly Patients. Journal of the American Medical Association. 2002;288(4):455–61. - PubMed
-
- Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-Year Follow-Up of Antidiabetic Drug Use, Nonadherence, and Mortality in a Defined Population with Type 2 Diabetes Mellitus. Clinical Therapeutics. 1999;21(6):1045–57. - PubMed
-
- Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A Refill Adherence Algorithm for Multiple Short Intervals to Estimate Refill Compliance (ReComp) Medical Care. 2007;45(6):497–504. - PubMed
-
- Cramer JA. A Systematic Review of Adherence with Medications for Diabetes. Diabetes Care. 2004;27(5):1218–24. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical